41862-09-3

Basic information

• Product Name: 6-AMINO-1-ETHYL-1H-PYRIMIDINE-2,4-DIONE
• Synonyms: 6-Amino-1-ethylpyrimidine-2,4(1H,3H)-dione;1-Ethyl-6-aMinouracil
• CAS NO: 41862-09-3
• Molecular Formula: C₆H₉N₃O₂
• Molecular Weight: 155.16
• Product Categories: Amines, Nucleotides, Bases & Related Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 41862-09-3.mol
• Article Data: 17

Chemical Properties

• Melting Point: 282 °C (decomp)
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.261g/cm³
• Refractive Index: 1.531
• PKA: 9.23±0.40(Predicted)
• CAS DataBase Reference: 6-AMINO-1-ETHYL-1H-PYRIMIDINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINO-1-ETHYL-1H-PYRIMIDINE-2,4-DIONE(41862-09-3)
• EPA Substance Registry System: 6-AMINO-1-ETHYL-1H-PYRIMIDINE-2,4-DIONE(41862-09-3)

Safety Data

• Hazardous Substances Data: 41862-09-3(Hazardous Substances Data)

Usage

Uses

1-Ethyl-6-aminouracil, is an intermediate in the synthesis of a series of new substituted Xanthines which have high affinity and selectivity for the human adenosine A2B receptors, and thus can be used as clinical candidate for chronic inflammatory airway diseases.

InChI:InChI=1/C6H9N3O2/c1-2-9-4(7)3-5(10)8-6(9)11/h3H,2,7H2,1H3,(H,8,10,11)

Upstream product

• 625-52-5 N-Ethylurea 
• 372-09-8 cyanoacetic acid 
• 105-56-6 ethyl 2-cyanoacetate 
• 41078-06-2 2-cyano-N-(ethylcarbamoyl)acetamide 

Downstream Products

• 63981-31-7 6-amino-1-ethyl-3-propylpyrimidine-2,4(1H,3H)-dione 
• 41862-13-9 6-amino-1-ethyl-3-methylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of 8-Mercapto-3,7-Dihydro-1H-Purine-2,6-Diones as Potent Inhibitors of SIRT1, SIRT2, SIRT3, and SIRT5

Sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylases. They regulate many physiological processes and play important roles in inflammation, diabetes, cancers, and neurodegeneration diseases. Sirtuin inhibitors have potential applications in the treatment of neurodegenerative diseases and various cancers. Herein, we identified new sirtuin inhibitors based on the scaffold of 8-mercapto-3,7-dihydro-1H-purine-2,6-dione. To elucidate the inhibitory mechanism, the binding modes of the inhibitors in SIRT3 were established by molecular docking, showing that the inhibitors occupy the acetyl lysine binding site and interact with SIRT3, mainly through hydrophobic interactions. The interactions were validated by site-directed mutagenesis of SIRT3 and structure-activity relationship analysis of the inhibitors. Consistently, enzyme kinetic assays and microscale thermophoresis showed that these compounds are competitive inhibitors to the acetyl substrate, and mix-type inhibitors to NAD+. Furthermore, we demonstrated that the compounds are potent SIRT1/2/3/5 pan-inhibitors. This study provides novel hits for developing more potent sirtuin inhibitors.

SUBSTITUTED XANTHINE DERIVATIVES

The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion ch

Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells

Eukaryotic elongation factor 2 kinase (eEF2K) is a key α-kinase that negatively regulates the extension step of protein synthesis, which consumes most of the energy and amino acids required for protein synthesis. Studies have found that eEF2K protein is related to the breast cancer. However, existing inhibitor effect has not achieved the desired effect in cancer therapy. Proteolysis target chimeric (PROTAC) technology is uses proteasome to degrade target protein to achieve the purpose of inhibiting tumour cell growth. Here, we reported that the use of PROTAC strategy in combining with star eEF2K inhibitor A484954 and its potential derivatives. Consequently, candidate compound 11l was found to degrade eEF2K and induce apoptosis in human breast carcinoma MDA-MB-231 cells. Together, these findings demonstrate that our eEF2K-targeting PROTAC small molecule would be a potential new strategy for future breast cancer therapy.